November 29, 2021
AbbVie Japan launched new formulations for its oral JAK inhibitor Rinvoq (upadacitinib) and Skyrizi (risankizumab), a psoriasis treatment, on November 26 following their NHI price listing the previous day. Rinvoq was approved in Japan in January last year for the...read more